Chemomab Therapeutics Ltd. - ADR

The momentum for this stock is not very good. Chemomab Therapeutics Ltd. - ADR is not a good value stock. Chemomab Therapeutics Ltd. - ADR is not a good growth stock. Tradey thinks it is not wise to invest in Chemomab Therapeutics Ltd. - ADR.

News

Chemomab Therapeutics (NASDAQ:CMMB) Announces Earnings Results

Ticker Report Chemomab Therapeutics (NASDAQ:CMMB - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.20...\n more…

Chemomab Therapeutics (NASDAQ:CMMB) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Ticker Report Chemomab Therapeutics (NASDAQ:CMMB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate...\n more…

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nChemomab Therapeutics just reported results for the second quarter of 2024.\nThe post CMMB Stock Earnings: Chemomab Therapeutics Reported...\n more…

Chemomab Therapeutics Reports Mid-Year Financials

TipRanks Financial Blog Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics Ltd. has released its unaudited interim condensed consolidated financial statements for t...\n more…

Chemomab Therapeutics reports Q2 EPS (1c) vs. (4c) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Globe Newswire TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ( Chemomab or the Company ), a clinical stage biotechnology company developing innovative...\n more…